Mubadala Bio Opens High-Potency Facility And Launches Three Essential Oncology Drugs In UAE

Mubadala Bio has unveiled a new high-potency facility at its subsidiary, Bioventure Healthcare. This launch includes three vital oncology medicines, some of which are being produced locally for the first time as branded generics. This initiative is a significant advancement in bolstering the UAE's pharmaceutical capabilities and ensuring a steady supply of essential treatments.

The newly constructed facility is tailored to handle high-potency drugs, including those used in oncology and hormone therapies. It adheres to the highest international safety and regulatory standards. The first products from this facility include Lenalidomide for treating myeloma, Pomalidomide for multiple myeloma, and Sunitinib for certain advanced cancers.

By introducing these crucial medications to the local market, Mubadala Bio aims to enhance drug security in the UAE. This move ensures a continuous supply of essential medications and provides more cost-effective treatment options for patients across the country.

Dr. Bakheet Al Katheeri, CEO of Mubadala's UAE Investments Platform and Chairman of Mubadala Bio, stated, "The launch of these locally produced oncology medications marks another important addition to Mubadala Bio’s growing portfolio." He emphasized that this milestone supports the development of a more advanced life sciences industry in the UAE.

Dr. Essam Mohamed, CEO of Mubadala Bio, expressed their commitment to strengthening the life sciences ecosystem in the UAE. By investing in local capabilities and launching essential oncology medications, they aim to expand access to medical therapies and ensure consistent local supply.

Hamad Husein Almarzooqi, Deputy CEO of Mubadala Bio, highlighted that the new high-potency facility and the launch of three new oncology medications not only expand their pharmaceutical capabilities but also reflect their commitment to providing reliable, high-quality medical products.

Strategic National Goals

The establishment of this high-potency facility and introduction of locally produced oncology medicines align with Mubadala Bio’s broader strategy. Their goal is to enhance national drug security and ensure a consistent supply of essential treatments within the UAE.

This initiative represents a major step forward in strengthening local pharmaceutical production capabilities. It ensures that critical treatments are readily available to healthcare providers and patients throughout the region.

With inputs from WAM